Alto Neuroscience, Inc. (NYSE:ANRO) Stock Rated “Moderate Buy” by Wall Street Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $37.88.

Several equities analysts have commented on ANRO shares. Wall Street Zen cut shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research report on Saturday, September 12th. Wedbush upped their target price on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. HC Wainwright increased their price target on Alto Neuroscience from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, October 19th. Zacks Research raised Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Finally, BTIG Research lifted their price target on Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th.

Insider Transactions at Alto Neuroscience

In other news, CFO Nicholas Smith sold 110,830 shares of the firm’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $26.58, for a total transaction of $2,945,861.40. Following the completion of the sale, the chief financial officer directly owned 24,060 shares of the company’s stock, valued at $639,514.80. This trade represents a 82.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 11.25% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently made changes to their positions in ANRO. Bank of New York Mellon Corp purchased a new stake in Alto Neuroscience during the second quarter worth about $2,014,000. AWM Investment Company Inc. bought a new stake in Alto Neuroscience in the second quarter worth about $2,111,000. Jennison Associates LLC bought a new stake in Alto Neuroscience in the first quarter worth about $8,687,000. Perceptive Advisors LLC boosted its stake in Alto Neuroscience by 12.6% in the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after acquiring an additional 225,500 shares during the last quarter. Finally, Orbimed Advisors LLC boosted its stake in Alto Neuroscience by 34.0% in the first quarter. Orbimed Advisors LLC now owns 167,500 shares of the company’s stock valued at $3,765,000 after acquiring an additional 42,500 shares during the last quarter.

Alto Neuroscience Stock Up 3.4%

Alto Neuroscience stock opened at $28.75 on Wednesday. Alto Neuroscience has a fifty-two week low of $10.80 and a fifty-two week high of $37.48. The stock has a market cap of $1.13 billion, a PE ratio of -11.88 and a beta of 1.42. The firm’s 50-day simple moving average is $26.71 and its 200 day simple moving average is $24.43. The company has a debt-to-equity ratio of 0.07, a quick ratio of 14.85 and a current ratio of 14.85.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.13. Research analysts predict that Alto Neuroscience will post -2.69 EPS for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.